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OBJECTIVE—Development of antigen-speciﬁc strategies to
treat or prevent type 1 diabetes has been slow and difﬁcult
because of the lack of experimental tools and deﬁned biomarkers
that account for the underlying therapeutic mechanisms.
RESEARCH DESIGN AND METHODS—The type 1 diabetes
PhysioLab platform, a large-scale mathematical model of disease
pathogenesis in the nonobese diabetic (NOD) mouse, was used
to investigate the possible mechanisms underlying the efﬁcacy of
nasal insulin B:9-23 peptide therapy. The experimental aim was
to evaluate the impact of dose, frequency of administration, and
age at treatment on Treg induction and optimal therapeutic
outcome.
RESULTS—In virtual NOD mice, treatment efﬁcacy was pre-
dicted to depend primarily on the immunization frequency and
stage of the disease and to a lesser extent on the dose. Whereas
low-frequency immunization protected from diabetes atrributed
to Treg and interleukin (IL)-10 induction in the pancreas 1–2
weeks after treatment, high-frequency immunization failed.
These predictions were conﬁrmed with wet-lab approaches,
where only low-frequency immunization started at an early
disease stage in the NOD mouse resulted in signiﬁcant protection
from diabetes by inducing IL-10 and Treg.
CONCLUSIONS—Here, the advantage of applying computer
modeling in optimizing the therapeutic efﬁcacy of nasal insulin
immunotherapy was conﬁrmed. In silico modeling was able to
streamline the experimental design and to identify the particular
time frame at which biomarkers associated with protection in
live NODs were induced. These results support the development
and application of humanized platforms for the design of clinical
trials (i.e., for the ongoing nasal insulin prevention studies).
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T
ype 1 diabetes is a complex and multifactorial
autoimmune disease, in which, (pro-) insulin-
speciﬁc T-cell responses have been described in
lymphocytes obtained from nonobese diabetic
(NOD) mice and (pre-)diabetic patients (1–4). In NOD
mice, the insulin B:9-23 peptide sequence is a dominant
epitope, and a single amino acid substitution in position 16
(B16:A) confers protection from the disease (5–7). Anti-
gen-speciﬁc immunotherapies with whole insulin and
B:9-23 peptide have been successful in preventing diabetes
in NOD mice when administered via the subcutaneous,
oral, or nasal route or via intramuscular DNA vaccination
(8–18). The success in halting disease progression in
prediabetic mice prompted physicians to establish similar
protocols to test safety and efﬁcacy in human prediabetic
or diabetic subjects. To this end, clinical trials with nasal
or oral whole insulin were conducted, which proved to be
safe. However, diabetes progression was only slightly
affected in a subset of insulin antibody–positive patients
treated with oral insulin in the Diabetes Prevention Trial–
Type 1 (19–24). In contrast, nasal insulin phase I–II trials
in Finland (21,24) and in Australia (20), during which
insulin was administered daily, failed to provide therapeu-
tic efﬁcacy. Highlighting the difﬁculties we are facing to
rationally translate antigen-speciﬁc therapies to humans,
there are conﬂicting reports on the efﬁcacy of nasal B:9-23
peptide immunization in the NOD mouse. Taken together,
these studies suggest that the manner by which insulin
therapy is administered is important (25,26). Many vari-
ables may inﬂuence efﬁcacy, including dose, frequency of
administration, and the stage of the disease. Systematic
investigation of each of these variables and combinations
thereof is experimentally impractical because of the time
constraints of in vivo studies, therefore necessitating
biosimulation approaches.
The type 1 diabetes PhysioLab platform is a top-down,
outcome-focused, large-scale mathematical model com-
posed of ordinary differential and algebraic equations
(27,28). This model reproduces type 1 diabetes pathogen-
esis in female NOD mice from birth until disease onset,
with extensive representation of critical biological pro-
cesses that were described in the literature and take place
in the pancreas, the pancreatic-draining lymph nodes
(PDLN), the gut, the nasal-associated lymphoid tissue
(NALT), and the peripheral blood.
In the present study, we used a cohort of virtual NOD
mice (VM) with diversity in underlying pathophysiology to
investigate how variations in dose, frequency, and age at
treatment initiation may impact the efﬁcacy of nasal B:9-23
peptide therapy. The VM program was designed based on
the following assumptions: 1) induction of Treg is beneﬁ-
cial for disease prevention, 2) induction of Th1 responses
(interferon [IFN] ) is detrimental for diabetes progres-
sion, whereas 3) induction of Th2 responses (interleukin
[IL]-10 and IL-4) favor disease protection. In silico inves-
tigation of the underlying mechanisms predicted that too
frequent nasal B:9-23 immunization would inhibit IL-10
induction and the generation of adaptive Treg (aTreg),
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model also aided in deﬁning the optimal time frame in
which Treg and IL-10 would be induced after immuniza-
tion, thereby mapping the timing for both as crucial
biomarkers.
Laboratory experiments conﬁrmed many of these pre-
dictions, establishing immunization frequency and induc-
tion of IL-10
 Treg as important considerations for the
design of future clinical trials. Interestingly, in the initial
and follow-up Peakman studies (2,29), it became evident
that naturally occurring circulating islet-speciﬁc IL-10–
producing cells regulate proinﬂammatory Th1 responses
in healthy individuals by linked suppression. This suggests
than in certain circumstances, given the heterogeneity of
human type 1 diabetes, IL-10 production could be sufﬁ-
cient in sustaining prolonged antigen-speciﬁc tolerance.
Future and ongoing trials might beneﬁt from less frequent
immunization, for example the ongoing nasal insulin stud-
ies in Australia (20). Moving forward, better deﬁning the
immunological parameters that could serve as biomarkers
is of particular importance for improving the previously
failed clinical trials (19–23,30) and for increasing the
chance of success (31,32).
RESEARCH DESIGN AND METHODS
Pharmacokinetic modeling of B:9-23 therapy. The pharmacokinetic (PK)
proﬁle for nasal B:9-23 in the blood and NALT was approximated using
published data for nasal delivery of the Ac1-9 peptide, used to induce
tolerance in murine experimental autoimmune encephalomyelitis (33).
VM. VM were generated and validated as previously described (28). Brieﬂy,
individual VM were generated to represent variations in underlying physiology
(supplementary Table 1, available at http://diabetes.diabetesjournals.org/cgi/
content/full/db10-0561/DC1) by adjusting parameters representing various
physiological processes. VM were then tested against a panel of internal
validation protocols. Where necessary, parameter values were adjusted so
appropriate behaviors to internal validation protocols were achieved. VM
were considered valid if no further adjustments were necessary to pass a
series of external validation protocols.
Experimental wet-lab NOD mice. NOD/LtJ female mice were purchased
from The Jackson Laboratories (Bar Harbor, ME) and maintained in the La
Jolla Institute for Allergy and Immunology under pathogen-free conditions
and handled in accordance with protocols approved by the organization’s
animal care and use committee.
Glucose monitoring. Blood glucose was monitored weekly with the One-
Touch Ultra (LifeScan, Milpitas, CA) monitoring system. Diabetes was deﬁned
as two consecutive blood glucose values 16.67 mmol/l.
B:9-23 peptide treatments. Amino acid sequence: SHLVEALYLVCGERG
was purchased from Abgent (San Diego, CA) with 95% purity. Nasal
administration: B:9-23 was diluted in sterile 1 PBS before given in the mouse
nostril. Nasal immunization started either at 4 or 9 weeks of age, and two
protocols were followed (high-frequency: 4, 9, 10, 11, 12, and 13 weeks of age
and low-frequency: 4, 9, and 13 weeks of age). In some cases, the peptide was
repeatedly given after 13 weeks of age every 4 weeks. The peptides were
administered at each indicated time point for 3 consecutive days.
Intra-islet T-cell puriﬁcation. Pancreata were digested with collagenase P
(Roche Molecular Diagnostics, Pleasanton, CA), and islets were separated on
a ﬁcoll gradient (Histopaque 1077; Sigma-Aldrich, St. Louis, MO). Next, islets
were dissociated into single cells. A mixture of islet cells and lymphocytes was
used for further analysis.
Flow cytometry. Single-cell suspensions, after a 2.4G2 blocking step, were
stained with the directly conjugated antibodies: CD4-Paciﬁc blue, CTLA-4-PE,
CD25-FITC, and CD127-PeCy7 (BD Pharmingen, Biolegend, or eBioscience,
San Diego, CA) (isotype controls for all antibodies were included). For
intracellular Foxp3 detection, cells were ﬁxed with Fix/Perm buffer and
stained with anti–Foxp3-APC (eBioscience). Cells were acquired on a LSRII
ﬂow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree-
star, Ashland, OR).
Assessment of cytokine production by single lymphoid cells (ELIspot).
IL-10, IL-4, and IFN (BD Pharmingen and Biolegend) produced by lympho-
cytes were detected by ELIspot as previously described (34).
Histology. Pancreata were immersed in Tissue-Tek OCT (Bayer, Torrance,
CA) and quick frozen on dry ice, and 6-m tissue sections were prepared.
Sections were stained for insulin and CD4 or CD8 as previously described
(34). To detect Foxp3 by immunoﬂuorescence (IFS), primary antibody (anti–
Foxp3-FITC, clone FJK-16s [4 mg/ml]) was used and ampliﬁed with Alexa 488
rabbit anti-ﬂuorescein (12.5 mg/ml) and Alexa 488 goat anti-rabbit (7.5 mg/ml).
To detect CD4, anti–CD4 biotin (3 mg/ml) followed by Alexa 647–conjugated
streptavidin (1/1,000) was used. After ﬁxation with 4% paraformaldehyde,
insulin was detected with polyclonal guinea pig anti-swine insulin (1/140)
followed by Alexa ﬂuor 594–conjugated anti–guinea pig (1/1,000) (35). Slides
were mounted with Slowfade Gold Antifade Reagent and visualized under a
Nikkon Marianas microscope. Insulitis scoring was performed as previously
described (34).
Antibody treatments. Anti–IL-10 (clone JES5-2A5) was purchased from BD
Pharmingen. Antibody-treated or control (IgG isotype treated) mice received
125 g of antibody intreperitoneally twice at 5, 6, 10, 11, 14, and 15 weeks of
age. Mice received a total of 12 antibody injections.
Intracellular cytokine staining and adoptive transfer experiments.
CD8-depleted lymphocytes from 30-week-old nasal B:9-23–treated normo-
glycemic mice were cultured with 10 g/ml B:9-23 in the presence of 50
units/ml rhIL-2 for 3 days. Next, cells were either stimulated with 5 and 2.5
g/ml plate bound anti-CD3 and soluble anti-CD28, respectively, or 10 g/ml
B:9-23 with or without 50 units/ml rhIL-2 before being assayed for intracellular
cytokine staining with the BD cytoﬁx/cytoperm kit. After B:9-23/IL-2 stimula-
tion, cells were collected using the mouse IL-10 secretion assay (Miltenyi
Biotech, Auburn, CA) according to the manufacturer’s protocol. Approxi-
mately 1  10
6 IL-10
 or IL-10
 puriﬁed lymphocytes were adoptively
transferred intravenously into 6- to 8-week-old not previously manipulated
NOD mice.
Statistical analysis. Data are expressed as a means  SD. The statistical
signiﬁcance of the difference between means was determined using the
two-tailed Student t test or the log-rank test. *P  0.05; **P  0.01; ***P 
0.005.
RESULTS
Unexplained divergences in efﬁcacy with various
therapeutic nasal B:9-23 regimens. Nasal B:9-23 pep-
tide therapy has been used with mixed efﬁcacy to induce
tolerance in prediabetic NOD mice. A comparison of all
published protocols shows differences in dose and fre-
quency of administration. Daniel et al. (9) showed that 40
g of B:9-23 given over 3 consecutive days at 4 weeks of
age and then again every 4 weeks beginning at 9 weeks of
age induced tolerance. By contrast, Kobayashi et al. (12)
did not observe efﬁcacy when 20 g of the peptide was
given over 5 consecutive days at 4 weeks of age and then
once a week for 5 weeks thereafter. Because the impact of
age at treatment initiation had not been assessed in either
of these studies, and to obtain further constraints for the
modeling effort, we used one additional protocol. In these
experiments, nasal B:9-23 therapy failed to confer protec-
tion at two different doses (40, 100 g/mouse) when
immunizations were started in 10-week-old mice (Fig. 1A
and B). The complex differences between these immuni-
zation protocols provided the rationale for computer mod-
eling to more precisely deﬁne our experimental options.
Impact of dose and age at treatment initiation on the
efﬁcacy of nasal B:9-23 peptide therapy. VM were
calibrated to capture the above-described wet-lab experi-
ments including the Daniel and Kobayashi protocols (sup-
plementary Table 1). Subsequently, this VM cohort was
used to assess the impact of three major parameters: dose,
frequency of administration, and age at treatment initia-
tion on therapeutic efﬁcacy. Dose responses were simu-
lated for all reported protocols, as shown in Fig. 1C.A
biphasic efﬁcacy proﬁle was predicted to occur with all
three protocols, similar to what had previously been
described for mucosal insulin (36) and cholera toxin B
administrations (8). Importantly, efﬁcacy was predicted
over a much larger range at lower doses for the Daniel
protocol, which administered insulin peptide at less fre-
quent dosing periods. Thus, variations in dosing protocol
can impact the therapeutic dose window and pose a
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protocols were predicted to be effective at much higher
doses, solubility concerns will preclude using such doses
experimentally. Efﬁcacy of nasal B:9-23 was predicted to
decrease if treatment was started at a later age (supple-
mentary Fig. 1A and B). To test this prediction, the Daniel
protocol was initiated in vivo in older NOD mice, at 9
weeks of age. Treatments that began at 9 instead of 4
weeks of age showed a lesser protective effect (supple-
mentary Fig. 1C), consistent with the simulation results.
More frequent immunization is predicted to interfere
with efﬁcient Treg induction that is required to
protect from type 1 diabetes. Three major cell popula-
tions contributing to disease pathogenesis are represented
in the PhysioLab platform: Th1, Th2 cells, and Treg
(supplementary Table 2). Both adaptive (aTreg) and natu-
ral (nTreg) are represented, with aTreg comprising char-
acteristics of both Tr1 and Th3 cells in the model. To gain
a better understanding of the mechanisms underlying the
efﬁcacy of nasal B:9-23 therapy, we selectively turned off
various of those mechanisms and reassessed the VM over
a speciﬁed dose range after B:9-23 nasal immunization
following the von Herrath protocol (Fig. 2A). At effective
low doses, induction of B:9-23–speciﬁc Treg and Th2 cells
were predicted to confer protection (blue line), whereas
peripheral T-cell deletion (green line) was less important.
Within both characterized Treg populations, nTreg induc-
tion did not seem to be important in conferring protection
after nasal B:9-23 immunization, and it was induced by all
three protocols in the NALT (Fig. 2B). In contrast, ineffec-
tive doses were predicted to be the result of aTreg deletion
in the NALT because turning off this mechanism resulted
in protection of all the VM (orange line). Closer looks at
Treg dynamics in the model revealed that aTreg, however,
was induced to a much greater extent by the effective
Daniel protocol (Fig. 2C). More importantly, induction of
aTreg by the ineffective protocols appeared to be actually
hampered by the frequent, weekly immunizations, suggest-
ing that too frequent immunizations might lead to aTreg
deletion.
More frequent immunization decreases efﬁcacy of
nasal B:9-23 therapy in vivo by impairing Treg induc-
tion. To test the hypothesis that too frequent immuniza-
tion is detrimental for Treg induction in vivo, mice were
divided into high- and low-frequency immunization
groups. Two speciﬁc immunization protocols based on
predictive outputs from the platform were implemented in
the wet lab, described in Table 1. No protection was
predicted in any of the VM following the high-frequency
protocol (Fig. 3A). Evaluation of the antidiabetogenic
properties of B:9-23 peptide immunizations in vivo accord-
ing to both protocols showed that indeed in live NOD mice
the low-frequency protocol was more effective than the
high-frequency one (Fig. 3B). In all cases, treatment was
initiated at the 4-week-old periinsulitis stage, and the mice
were immunized with 40 g of B:9-23. It is important to
note here that simulated responses to alternate protocols
provide insight into which protocols are most robust
against variability or unknowns in the underlying disease
and are to be interpreted as relative ranking of protocols
rather than quantitative predictions of protection.
Moreover, the PhysioLab platform predicted changes in
Treg populations within the NALT, islets, blood, and
PDLN, as described in Fig. 3C–E. Elevations in Treg were
predicted to peak at 	1–2 weeks after each round of
immunization in the NALT and blood but not in the PDLN
for the low-frequency protocol (blue line). In contrast, no
Treg elevation was predicted after the follow-up immuni-
zation period using the high-frequency protocol. We mea-
sured blood Treg between 10 and 12 weeks of age,
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FIG. 1. Two different amounts of B:9-23 peptide cannot protect from diabetes when administered nasally in 10-week-old NOD mice. A: Graphic
representation of the B:9-23 nasal immunization protocol followed. Ten-week-old NOD mice received 40 or 100 g B:9-23 peptide nasal every
other day for the ﬁrst 2 weeks and once a week for the following 5 weeks. B: There was no protection from diabetes after following the protocol
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when blood glucose was >16.67 mmol/l for two consecutive weekly measurements. C: Multiphasic dose responses were predicted for the protocols
presented in supplementary Table 1. Nasal B:9-23 peptide therapy was simulated for the Daniel (green solid line), Kobayashi (red solid line), and
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test predictions of the model. In agreement with the in
silico predictions, elevated Treg frequency deﬁned as
CD4
CD25
Foxp3
 (37) was observed at weeks 10 and 11
in the blood of mice immunized with the low-frequency
protocol (Fig. 3F–H). Interestingly, we also observed in
these wet-lab studies that reduced Treg expansion oc-
curred as a result of more frequent dosing, which was
associated with lack of protection from diabetes. In addi-
tion, no signiﬁcant differences were observed for Treg
levels in the PDLN (Fig. 3G). Altogether, these results
provide additional conﬁdence in the model and suggest
that Treg induction and subsequently protection from
diabetes in the NOD mice by nasal B:9-23 administration
will perhaps more easily occur in vivo when a lower-
frequency immunization protocol is chosen.
Lower frequency of nasal B:9-23 immunization de-
creases insulitis and increases Treg frequency within
the inﬂamed islets. To determine the extent of islet
inﬁltration following nasal B:9-23 immunization, pancreata
from nondiabetic mice of all treatment groups were histo-
logically examined at 12 weeks of age. As shown in Fig.
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FIG. 2. Loss of efﬁcacy after high nasal B:9–23 immunization frequency is predicted to be attributed to lower induction of aTreg in the NALT. A:
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TABLE 1
Nasal B:9-23 peptide protocols optimized and recommended by the type 1 diabetes PhysioLab platform
Protocol
Initial treatment Follow-up treatment
In silico
prediction
Age
(weeks)
Dose
(g) Schedule Age (weeks)
Dose
(g) Schedule
Low frequency 4 40 3 consecutive days 9 and 13 40 3 consecutive days Protective
High frequency 4 40 3 consecutive days 9, 10, 11, 12,
and 13
40 3 consecutive days Not protective
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low-frequency protocol was minimally inﬂamed or had
mild peri-insulitis. In contrast, most of the islets of normo-
glycemic mice that received the high-frequency immuniza-
tion protocol had much greater CD4
 and CD8
 T-cell
inﬁltrates. Furthermore, when scoring of the islets was
undertaken, mice that received the high-frequency proto-
col showed a relatively greater degree of insulitis than the
control mice.
Intra-islet Treg numbers were predicted to be increased
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FIG. 3. Validation of predicted nasal B:9-23 immunization frequency inﬂuence on diabetes incidence and Treg levels by laboratory measurements.
A and B: High-frequency immunization decreases efﬁcacy. A: In silico simulation showing expected impact on blood glucose (mmol/l) in a
representative virtual NOD mouse. B: Nasal B:9-23 administration upon low-frequency immunization protects from type 1 diabetes. Percentage
of mice developing diabetes after high- or low-frequency immunizations started at 4 weeks of age with 40 mg B:9-23 peptide. At least 12 mice were
included in each experimental group. Each immunization protocol was repeated in at least two independent experiments. *P < 0.05 between
immunization groups. C–E: High-frequency immunization is predicted to decrease efﬁcacy because of the deletion of aTreg in the NALT.
Simulation results for Treg levels in the NALT (C), PDLN (D), and peripheral blood (E) in a representative VM. The green boxes indicate the
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low-frequency immunization induces Treg and protects from type 1 diabetes. Treg frequency (%CD25
Foxp3
 gated on CD4
CD127
low, >95% of
CD4
 were CD127
low) in the spleen (F), PDLN (G), and blood (H) over time after high- or low-frequency immunizations (n  4 mice per group).
*P < 0.05; **P < 0.01; ***P < 0.005 between immunization groups. Data are means  SE.
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nization protocol (Fig. 4D). To selectively identify and
quantify Treg within the islets, immunoﬂuorescent stain-
ing for the presence of Foxp3
 cells was conducted in
pancreatic sections. Interestingly, highly inﬂamed islets
with a high Treg density were indicative of treatment
success. In the low-frequency treatment group, a remark-
able increase in Treg density, particularly in islets with
high degree of inﬂammation (score 3), was seen (Fig. 4E
and F) (islets with similar degree of inﬂammation were
compared between groups). Therefore, after B:9-23 nasal
treatment, a relatively linear correlation between degree
of insulitis and Treg frequency was observed: the higher
the inﬂammation, the more Foxp3
 cells present, with
frequency that exceeded 20%. In contrast, in untreated
mice a slight decline in Foxp3
 cells frequency in islets
with higher degree of inﬂammation was observed. This
may be because of an inherent defect in expressing
sufﬁcient amounts of CD25 and Bcl-2, resulting in early cell
death (38).
Prediction and validation of increased islet levels of
IL-10 following the low-frequency protective B:9-23
immunization protocol. Simulation results predicted an
elevation in IL-10 and IL-4 but a decline in IFN intra-islet
cytokine levels at 11–12 weeks of age following the
low-frequency immunization protocol (Fig. 5A–C). On the
other hand, for the same time point, in mice immunized
with the high-frequency protocol, predictions showed re-
duced intra-islet IL-10 levels. To test these predictions,
IL-10, IL-4, and IFN were measured by ELIspot immuno-
assay. Although IL-17 was shown to be involved in hinder-
ing nasal peptide tolerance induction in experimental
autoimmune encephalomyelitis (39), here it was not mod-
eled due to its insufﬁcient knowledge in diabetes patho-
genesis. Interestingly, as shown in Fig. 5D and E, an increase
of IL-10 production in the intra-islet–derived lymphocytes
was observed. Similarly in the PDLN, as shown in Fig. 6C,
IL-10 levels were increased, whereas IL-4 levels were slightly
but not signiﬁcantly higher in the blood and spleen of mice
that had received the low-frequency protocol. Moreover, IL-4
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were not different. Unexpectedly, IFNwas elevated with the
low-frequency protocol particularly in the spleen Fig. 6A.
This observation could reﬂect the unconventional protective
role for IFN, whereby IFN may suppress pathogenic IL-17
producing T-cells (40).
Further in silico analysis suggested that effective nasal
B:9-23 treatment should be most sensitive to IL-10 and
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test the importance of IL-10 in B:9-23–mediated tolerance,
mice receiving the low-frequency protocol were treated
intraperitoneally with anti–IL-10 neutralizing antibody.
Given that the model predicts a delay of 1–2 weeks after
nasal immunization for aTreg (Fig. 2C) and IL-10 levels
(Fig. 5C) to increase, anti–IL-10 was administered in vivo 1
and 2 weeks after each nasal immunization (i.e., at 5, 6, 10,
11, 14, and 15 weeks of age). In vivo IL-10 neutralization
abrogated the nasal B:9-23 protective effect as shown in
Fig. 7B. Interestingly, IL-10 neutralizing antibody had to be
administered after each round of nasal B:9-23 treatment,
and normal progression to diabetes was not restored when
it was only administered at 10 and 11 weeks of age, while
anti–IL-10 treatment alone slightly but not signiﬁcantly
increased disease progression in untreated NOD mice
(data not shown).
Further adoptive transfer studies shown in Fig. 7C and
D conﬁrmed that IL-10–producing Treg could transfer
protection following nasal B:9-23 treatment. In these stud-
ies, CD4
 T-cells derived from normoglycemic 	30-week-
old nasal B:9-23–protected mice were activated with
B:9-23 and IL-2 in vitro leading to a signiﬁcant number (2%)
of IL-10
 B:9-23–speciﬁc cells. IL-10
 cells were puriﬁed
and adoptively transferred into nonimmunized 6- to
8-week-old NOD hosts. Importantly, short-term protection
was only conveyed by the IL-10
 Treg (Fig. 7C). Alto-
gether, these results demonstrate that IL-10 is essential for
protection from diabetes after nasal B:9-23 treatment, thus
conﬁrming our in silico predictions.
DISCUSSION
Although many approaches to induce antigen-speciﬁc tol-
erance to prevent type 1 diabetes have been successful in
the NOD mouse, translating these strategies to humans
has been challenging given the multitude of variables that
can affect the outcome (41). In NOD mice, factors related
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to systematically investigate in the laboratory due to the
very large number of possible combinations of multiple
parameters. Furthermore, intramouse variability of dis-
ease pathogenesis even in inbred organisms presents
another complicating issue necessitating the use of groups
with large numbers of mice. Last, development of reliable
biomarkers that, for example, would track the successful
induction of Treg at the correct time postimmunization
has also been slow, because the optimal time point of
sample recovery is unknown. Here, we demonstrate that
biosimulation can be a useful tool to explore variations in
the protocol regimen and deﬁne optimal time points to test
Treg induction as well as point toward crucial biologic
factors mediating tolerance. Overall, our present study
demonstrates that simulation results can be used to focus
and guide laboratory experiments and optimize treatment
regimens for type 1 diabetes. Our in silico simulation
investigated the effect of dose, frequency, and age at
initiation on the efﬁcacy of nasal B:9-23 treatment in a
cohort of VM. Nasal B:9-23 immunization appeared to be
efﬁcacious at low and high doses but not at intermediate
doses. With respect to age, efﬁcacy was generally pre-
dicted to be biphasic and better when treatment was
started earlier. In addition, and possibly of high impor-
tance for ongoing nasal insulin trials, in silico analysis
predicted that too frequent immunization was ineffective,
while lower immunization frequency induced increased
IL-10 levels and aTreg induction. This resulted in a much
larger efﬁcacious dose range for lower insulin doses that
lead to efﬁcient Treg induction. In other words, by reduc-
ing the frequency of insulin administration, even higher
doses could still result in tolerance. This might have
important implications for human trials with nasal and
oral insulin, where the optimal efﬁcacious dose is still
unknown but where the immunization frequency could be
reduced.
The in silico prediction that too frequent immunization
can be detrimental was corroborated by subsequent in
vivo experiments. Furthermore, the predicted underlying
mechanism of increasing Treg levels with low-frequency
dosing was also conﬁrmed, as was the association with
higher IL-10 levels in the pancreas. Moreover, in vivo
blockade of IL-10 and adoptive transfer of B:9-23–speciﬁc
IL-10–producing Treg attributed a key role to this cytokine
in nasal B:9-23 therapy. Interestingly, the role of IL-10,
derived by induced Tr1/Th3 cells or CD4
CD25
Foxp3

aTreg in nasal autoantigen-induced tolerance, has been
described before (42–44). Here, we cannot dissect the
relative involvement of both cell populations in establish-
ing nasal tolerance, as the aTreg representation in the
model is generic to encompass characteristics of Tr1 and
Th3 cells. Although further experimentation is necessary
to thoroughly address each mechanism, our results pro-
vide evidence that the top-down approach to modeling
disease we applied had sufﬁcient detail to be predictive.
While our laboratory experiments provided additional
validation for the predictive capacity of the type 1 diabetes
PhysioLab platform, not all model predictions were con-
sistent with laboratory experiments (summarized in sup-
plementary Table 4). For example, Treg frequency in the
pancreas was predicted to be increased predominantly by
the low-frequency protocol at the time point indicated but
was actually elevated by both low- and high-frequency
protocols compared with controls. However, high-fre-
quency immunization induced increased insulitis, whereas
it delayed type 1 diabetes progression to a limited degree.
Presumably, the high degree of lymphocytic inﬁltration
was counterregulated by an increased frequency of Tregs
in the islets in this scenario. Since mucosal autoantigen
administration can at very high doses induce cytotoxic
T-cell responses accelerating type 1 diabetes onset in mice
(45), caution should be taken when applying antigen-
speciﬁc immunotherapy at very high dosages or very high
frequencies, or both, for the treatment of human autoim-
mune disease. While our top-down modeling approach is
not infallible and has some deﬁciencies and inaccuracies,
it is still able to have good predictive capacity. As model-
ing is an iterative process, these discordant data may be
incorporated into the next generation of VM to build upon
and enhance the predictive capacity of the model.
The wet-lab observation that low-frequency dosing may
increase IFN levels in the spleen also suggested that IFN
might have a yet unappreciated role in type 1 diabetes in
the NOD mouse. A recent report (40) indicated that IFN
could, by reducing IL-17, have a protective role in autoim-
mune diabetes. The current version of the platform as-
sumes that IFN has only pathogenic effects and does not
have a representation for IL-17. This illustrates the need
for future expansion of the platform to include alternative
functions of IFN, and perhaps representation of Th17
cells and IL-17, to explore the potential impact of this
biology as its role in type 1 diabetes continues to emerge.
Overall, we can see here that one of the strengths of the
top-down modeling approach is that it can be predictive
despite lacking every possible detail. This study demon-
strates the utility of mechanism-based biosimulation meth-
ods to efﬁciently optimize dosing schedules where the
combinations of the variables that need to be tested in the
laboratory render the task impractical and to provide
guidance for when to measure candidate biomarkers. Our
results suggest that immunization frequency should be a
major consideration for ongoing clinical trials that aim to
induce tolerance in humans and that IL-10 and Treg levels
may be useful biomarkers to predict efﬁcacy of treatment.
Last, humanization of the PhysioLab platform should be
warranted to give guidance for improved design of future
clinical trials. What we envision in humans, where type 1
diabetes is a lot more heterogeneous, is the generation of
a general platform, which will be easily adapted to each
individual characteristics (i.e., family history, genetic
background, number and titers of autoantibodies, glycosy-
lated hemoglobin, and C-peptide levels). Thus, personal-
ized simulations will become possible and customized
treatments would be suggested on an individual basis.
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